Analysts Feel Price for Lek Takeover too Low for Big Shareholders
Ljubljana, 29 August - The takeover price that Swiss pharmaceutical giant Novartis has offered for the takeover of Slovenian drug maker Lek (SIT 95,000/EUR 417.3 a share) is quite low for big shareholders and solid for the smaller shareholders, Slovenian market analysts agree. While some said Thursday that the price should be set at SIT 100,000/EUR 439, others were convinced that it could even climb to SIT 120,000/EUR 527.
The rest of this news item is available to subscribers.
The news item consists of 1.705 characters (without spaces) or 338 words words.
Buy the news item. Price: 2 tokens; on account: 0 tokens.